Innoviva, Inc.
INVAHealthcareNASDAQBiotechnology · Last scanned Jun 1, 2026
Scan Results
Daily timeframeInnoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. The company carries a $1.58B market cap, placing it firmly in the small-cap category. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.
Market Cap
$1.58B
Beta
0.38
P/E (TTM)
3.42
P/E (Fwd)
9.69
EPS (TTM)
$6.26
EPS (Fwd)
$2.21
ROE
50.7%
ROA
6.7%
Cash
$611.9M
Total Debt
$331.4M
Free CF
$105.2M
52W Change
6.4%
Annual Financials
Cash vs Debt
With $611.9M in cash and $331.4M in debt, INVA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $105.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 50.7%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $331.3M (2022) to $411.3M (2025), reflecting a 24% increase over the period.
With a beta below 0.7, Innoviva, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing INVA.